Rossari Biotech Q4 FY26: Revenue up 18%, PAT up 34% YoY

Pat Growth 25pctEbitda Margin CompressionResults View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-7.4%1-day move

₹505.20

prior close

₹474.90

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2-0.2-0.1-0.1-7.4-5.6-5.0-4.8-2.9+7.7+0.4+3.5+3.1-0.1

Up moveDown movePending

AI summary

Rossari Biotech reported highest-ever quarterly revenue and EBITDA for Q4 FY26. Consolidated Q4 revenue grew 18% YoY to Rs. 684.9 cr, EBITDA rose 11% to Rs. 77.3 cr, and PAT jumped 34% to Rs. 46 cr. FY26 revenue grew 15% to Rs. 2,396.4 cr with PAT at Rs. 149.2 cr (up 9%). EBITDA margins compressed to 11.3% (Q4) and 11.9% (FY) due to raw material costs. Board recommended Rs. 0.50/share dividend. Unitop's Dahej ethoxylation capacity now at 66,000 MTPA.

Likely market impact

Strong quarterly revenue and PAT growth show business momentum, but margin compression from raw material costs and a modest Rs. 0.50 dividend may limit near-term excitement.